Vixarelimab
Based on 1 publication(s) in Google Scholar
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96.90%
- CAS 番号: 2243320-83-2
- 分子量:145.042 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Vixarelimab
More
生物活性
IgG4-G1-lambda2
Human
OSMR
Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) results in increased MCP-1/CCL2 levels at a concentration of 0.0001 μg/mL in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF) cells and a significant decrease in MCP-1/CCL2 levels in both cells at concentrations of 0.001 μg/mL or higher[1].
Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) pretreatment results in reduced levels of MCP-1/CCL2 in both Oncostatin M (OSM) induced as well as OSM plus IL-4 induced HEK and HDF cells and the maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG4-G1-lambda2
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Hela cells labelling OSMR (red) with Vixarelimab (anti-OSMR) (HY-P99519). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 2243320-83-2
-
性状 Liquid
-
分子量 145.042 kDa
-
Color Colorless to light yellow
-
SMILES
[Vixarelimab]
-
別名
KPL-716; BIIB-069; RG-6536
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Periodontol
Gingipain and oncostatin M synergistically disrupt kidney tight junctions in periodontitis-associated acute kidney injury. [Abstract]2024 Sep;95(9):867-879. PMID: 38963713
純度とドキュメンテーション
-
データシート (259 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)